INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01801 INNOVENT BIO

Trading 08-06 11:52:24

91.150

+0.850

+0.94%

High92.150	Low89.100	Vol5.22M
Open91.000	D1 Closing90.300	Amplitude3.38%
Mkt Cap158.69B	Tradable Cap158.69B	Total Shares1.74B
T/O473.76M	T/O Rate0.30%	Tradable Shares1.74B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":91.15,"timestamp":1785988319475,"preClose":90.3,"halted":0,"volume":5220983,"delay":0,"changeRate":0.00941306755260253,"floatShares":1741000000,"shares":1741000000,"eps":0.546210670282438,"marketStatus":"Trading","change":0.85,"latestTime":"08-06 11:52:24","open":91,"high":92.15,"low":89.1,"amount":473762401,"amplitude":0.033776,"askPrice":91.15,"askSize":21000,"bidPrice":91.1,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":0.546210670282438,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1785988800000},"marketStatusCode":2,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":90.3,"openAndCloseTimeList":[[1785979800000,1785988800000],[1785992400000,1786003200000]],"volumeRatio":1.040064,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5306,"impliedVolPercentile":0.5959},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2657577353","title":"Innovent Announces First Patient Dosed in Pivotal Registrational Study of Ibi363/Tak-928 (Pd-1/Il-2Α-Biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2657577353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657577353?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:00","pubTimestamp":1785974402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA6RJNM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KURE","LU2097828714.EUR","LU2097828474.EUR","LU2097828557.USD","LU2097828805.USD","HK0000165453.HKD","LU0455707207.USD","BK1161","LU2328871848.SGD","01801","BK1589","LU1969619763.USD","LU2097828631.EUR","LU2242644610.SGD","LU0502904849.HKD","LU2488822045.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107154360","title":"Citigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1107154360","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107154360?lang=en_us&edition=fundamental","pubTime":"2026-08-05 15:01","pubTimestamp":1785913278,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801.HK) reported first-half 2026 product revenue exceeding RMB 8.2 billion, representing a year-on-year increase of more than 55%, with second-quarter product revenue alone surpassing...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU0203347892.USD","LU1267930227.SGD","LU1506573853.SGD","IYF","LU2488822045.USD","IE00BSNM7G36.USD","BK1589","C","LU0162691827.USD","LU1074936037.SGD","LU0052756011.USD","BK1161","LU0455707207.USD","LU0310800965.SGD","BK4588","FTXO","LU1791807156.HKD","LU2456880835.USD","LU2097828714.EUR","LU1244550221.USD","LU2462157665.USD","LU2417539215.USD","BK4207","01801","LU0648001328.SGD","LU0314106906.USD","LU1366192091.USD","LU2125154778.USD","LU0170899867.USD","LU0130102774.USD","LU2097828474.EUR","BK4566","LU2125154935.USD","LU2328871848.SGD","BK4585","BK4504","BK1583","LU0098860793.USD","LU2097828557.USD","LU2097828805.USD","LU0203345920.USD","EWH","LU0980610538.SGD","LU1969619763.USD","LU0502904849.HKD","KURE","LU1162221912.USD","LU0128525689.USD","LU0072461881.USD","LU0320765646.SGD","LU1244550494.USD","LU2097828631.EUR","LU0477156953.USD","BK4534","LU2242644610.SGD","LU1668664300.SGD","BK4559","LU1201861249.SGD","LU2236285917.USD","LU0130517989.USD","LU1244550577.SGD","LU0106831901.USD","LU2360032135.SGD","TFNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154699784","title":"CLSA: INNOVENT BIO (01801) First-Half Product Revenue Significantly Exceeds Expectations, Serving as a Positive Catalyst for Stock Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1154699784","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154699784?lang=en_us&edition=fundamental","pubTime":"2026-08-05 15:00","pubTimestamp":1785913218,"startTime":"0","endTime":"0","summary":"CLSA has released a research report indicating that INNOVENT BIO (01801) reported product revenue of RMB 8.2 billion for the first half of 2026, representing a 55% year-on-year increase and far...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","BK1583","LU2488822045.USD","LU2328871848.SGD","HK0000165453.HKD","LU2097828474.EUR","LU2097828714.EUR","LU2097828557.USD","BK1589","LU0455707207.USD","LU0502904849.HKD","KURE","LU1969619763.USD","LU2242644610.SGD","LU2097828631.EUR","01801","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657910915","title":"Innovent Biologics' Product Revenue Surges 60% in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2657910915","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657910915?lang=en_us&edition=fundamental","pubTime":"2026-08-05 11:08","pubTimestamp":1785899286,"startTime":"0","endTime":"0","summary":"Innovent Biologics  said second-quarter product revenue exceeded 4.3 billion yuan, up about 60% from a year earlier, according to a Wednesday Hong Kong bourse filing.First-half product revenue topped 8.2 billion yuan, representing year-over-year growth of more than 55%.The growth was driven by strong sales of flagship products, including mazdutide, as well as broader market penetration of its tyrosine kinase inhibitor therapies included in China's National Reimbursement Drug List.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0455707207.USD","LU2097828557.USD","BK1589","BK1161","LU2328871848.SGD","LU2097828805.USD","LU2488822045.USD","HK0000165453.HKD","LU0502904849.HKD","LU2097828631.EUR","LU2097828474.EUR","LU2097828714.EUR","LU2242644610.SGD","KURE","LU1969619763.USD","01801","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657606599","title":"Innovent Biologics Jumps Most in 3 Weeks on Robust Product Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2657606599","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657606599?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:52","pubTimestamp":1785894772,"startTime":"0","endTime":"0","summary":"BUZZ-Innovent Biologics jumps most in 3 weeks on robust product revenue growth** Shares of Innovent Biologics Inc1801.HKjump 6.3% to HK$92.2, on track for the biggest one-day pct gain since July 15** Stock touches the highest level since July 24 in the second session of gain** The innovative medicine developer and producer says itsfirst half 2026 product revenueexceeds 8.2 bln yuan , up over 55% y/y, of which total revenue for the second quarter is up 60% y/y to over 4.3 bln yuan** YTD, stock up 18%, Hang Seng Biotech Index.HSBIOup 0.6%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N44201W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","LU2097828631.EUR","LU0502904849.HKD","BK1583","LU0455707207.USD","BK1147","01911","01801","LU2097828714.EUR","LU2097828805.USD","LU2488822045.USD","BK1161","LU2242644610.SGD","BK1589","LU1969619763.USD","LU2328871848.SGD","HK0000165453.HKD","LU2097828474.EUR","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189813572","title":"INNOVENT BIO shares open over 2% higher as first-half product revenue exceeds RMB 8.2 billion, marking a 55% surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1189813572","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189813572?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:34","pubTimestamp":1785893690,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801) opened more than 2% higher in Hong Kong trading, with shares climbing 2.48% to HKD 88.85 as of press time, recording a turnover of HKD 13.83 million.According to a company...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","KURE","BK4588","BK1583","VXUS","LU2242644610.SGD","01801","LU2097828557.USD","BK1589","LU0455707207.USD","LU1969619763.USD","BK1161","LU2097828805.USD","LU2488822045.USD","KCAI","HK0000165453.HKD","LU2097828474.EUR","LU2097828714.EUR","LU0502904849.HKD","LU2097828631.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127813339","title":"Movement Alert｜INNOVENT BIO Rises 5.77% in Regular Trading, H1 Product Revenue Exceeds RMB 8.2 Billion with 55%+ YoY Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1127813339","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127813339?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:34","pubTimestamp":1785893654,"startTime":"0","endTime":"0","summary":"On August 5, INNOVENT BIO rose 5.77% in regular trading, trading at HKD 91.25/share, with turnover of HKD 172 million.On the news front, the company released an insider information announcement...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107103839","title":"Hong Kong Listed Companies' News Digest: Innovent Bio's First-Half Product Revenue Exceeds RMB 8.2 Billion, Up Over 55% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1107103839","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107103839?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:18","pubTimestamp":1785892701,"startTime":"0","endTime":"0","summary":"Innovent Bio (01801) reported that its first-half product revenue surpassed RMB 8.2 billion, reflecting a year-on-year increase of more than 55%.Major DevelopmentsSEYOND (02665) has signed a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","LU2097828714.EUR","08646","LU1969619763.USD","LU2097828805.USD","KCAI","02665","LU2097828557.USD","LU0455707207.USD","BK1229","LU2328871848.SGD","BK1583","BK1589","LU2488822045.USD","LU2097828474.EUR","HK0000165453.HKD","LU2242644610.SGD","LU0502904849.HKD","LU2097828631.EUR","01801","BK1144","BK4588","BK1170","BK1105","02270","06951","BK1161","KURE","BK4585","BK1258"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657596147","title":"Innovent Biologics Says First Half 2026 Product Revenue Exceeds Rmb8.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2657596147","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657596147?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:16","pubTimestamp":1785892580,"startTime":"0","endTime":"0","summary":"BRIEF-Innovent Biologics Says First Half 2026 Product Revenue Exceeds RMB8.2 BillionAug 5 (Reuters)-Innovent Biologics Inc1801.HK:FIRST HALF 2026 PRODUCT REVENUE EXCEEDS RMB8.2 BILLION, UP OVER 55% Y/YFurther company coverage:1801.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4411GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU1969619763.USD","LU2242644610.SGD","LU2328871848.SGD","LU2488822045.USD","KURE","BK1589","LU2097828631.EUR","BK1161","HK0000165453.HKD","LU0455707207.USD","01801","LU2097828805.USD","BK1583","LU0502904849.HKD","LU2097828474.EUR","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141383116","title":"Innovent reports H1 2026 product revenue surpassing RMB 8.20 billion, up more than 55%; Q2 alone tops RMB 4.30 billion with 60% growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1141383116","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141383116?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:03","pubTimestamp":1785888209,"startTime":"0","endTime":"0","summary":"Innovent Biologics, Inc. (Innovent) announced unaudited product revenue of more than RMB 8.20 billion for the six months ended 30 June 2026, representing year-on-year growth exceeding 55%....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657593492","title":"Innovent Biologics - First Half 2026 Product Revenue Exceeds Rmb8.2 Bln, up over 55% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2657593492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657593492?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:01","pubTimestamp":1785888088,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4411GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828714.EUR","LU2097828557.USD","BK1589","LU2242644610.SGD","LU2488822045.USD","HK0000165453.HKD","KURE","LU2097828474.EUR","LU2328871848.SGD","01801","LU0502904849.HKD","LU1969619763.USD","LU2097828805.USD","LU2097828631.EUR","BK1583","BK1161","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186161829","title":"Movement Alert｜INNOVENT BIO Declines 3.52% in Regular Trading, Trading at 83.5 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1186161829","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186161829?lang=en_us&edition=fundamental","pubTime":"2026-08-03 09:45","pubTimestamp":1785721558,"startTime":"0","endTime":"0","summary":"On August 3, INNOVENT BIO declined 3.52% in regular trading, trading at 83.5 HKD/share, with turnover of 199 million HKD.Within the Biotechnology sector where INNOVENT BIO belongs, the overall sector...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356455","title":"Medtide Names Ding Lijun as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356455","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655356455?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:35","pubTimestamp":1785486901,"startTime":"0","endTime":"0","summary":"Medtide names Ding Lijun as CFONamed Ding Lijun as chief financial officer effective July 31, 2026; she was CFO of Inventronics (Hangzhou) from Feb 2025 to Jul 2026.Ding previously served as finance v","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL6fMHMp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU2097828557.USD","BK1141","LU2242644610.SGD","BK0247","BK0214","LU1969619763.USD","LU2097828714.EUR","LU0455707207.USD","300582","LU2328871848.SGD","BK1161","LU2097828474.EUR","LU2488822045.USD","BK1589","LU2097828631.EUR","LU0502904849.HKD","03880","BK1583","LU2097828805.USD","KURE","300577","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135680900","title":"China's domestic innovative drugs set for overseas revenue breakthrough as policy support strengthens","url":"https://stock-news.laohu8.com/highlight/detail?id=1135680900","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135680900?lang=en_us&edition=fundamental","pubTime":"2026-07-31 07:16","pubTimestamp":1785453390,"startTime":"0","endTime":"0","summary":"The Shanghai municipal government released its \"15th Five-Year Plan for Health Development\" on July 30, which includes measures to boost the research and development of innovative drugs and medical...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1770034418.SGD","LU2476274308.USD","BK1161","LU2097828631.EUR","LU2399975544.HKD","LU0561508036.HKD","LU2097828805.USD","09688","MEDX","06978","09926","IBBQ","LU0348784397.USD","HK0000165453.HKD","LU2097828474.EUR","LU1719994722.HKD","BK4588","LU0307460666.USD","LU0417516738.SGD","LU2097828557.USD","LU2778985437.USD","BK4585","KURE","LU0348825331.USD","LU1720050803.USD","LU0348783233.USD","LU2328871848.SGD","BK1574","LU0502904849.HKD","IE00BPRC5H50.USD","LU2476274720.SGD","VXUS","LU0417516571.SGD","LU1303224171.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1969619763.USD","LU1251922891.USD","LU0348767384.USD","BK1588","LU1961090484.USD","LU0634319403.HKD","159992","BK1589","LU0455707207.USD","LU0348827113.USD","LU0588546209.SGD","LU2242644610.SGD","LU0348766576.USD","LU0348735423.USD","06160","LU0417516902.SGD","KCAI","LU2488822045.USD","LNGR","LU0540923850.HKD","BK1500","01801","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145019134","title":"Movement Alert｜INNOVENT BIO Declines 3.12% in Regular Trading, Trading at 86.8 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1145019134","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145019134?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:18","pubTimestamp":1785381494,"startTime":"0","endTime":"0","summary":"On July 30, INNOVENT BIO declined 3.12% in regular trading, trading at 86.8 HKD/share, with turnover of HKD 405 million.Within the Biotechnology sector where INNOVENT BIO belongs, the overall sector...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177071062","title":"Obesity Specialty Standardized Weight Management Service System Initiative Launches in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1177071062","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177071062?lang=en_us&edition=fundamental","pubTime":"2026-07-26 22:41","pubTimestamp":1785076876,"startTime":"0","endTime":"0","summary":"On July 26, the \"Obesity Specialty - Standardized Weight Management Service System for Medical Institutions\" project, led by the Endocrine and Metabolic Obesity Diagnosis and Treatment Alliance,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU2097828474.EUR","LU0502904849.HKD","BK1589","KURE","LU2097828631.EUR","LU1969619763.USD","BK1583","LU2097828714.EUR","BK1161","LU2328871848.SGD","LU2097828805.USD","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","LU0455707207.USD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194435138","title":"Movement Alert｜Innovent Biologics Rises 3.04% in Regular Trading, BD Deal Catalyst and Biotech Sector Recovery Drive Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1194435138","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194435138?lang=en_us&edition=fundamental","pubTime":"2026-07-20 09:48","pubTimestamp":1784512088,"startTime":"0","endTime":"0","summary":"On July 20, Innovent Biologics rose 3.04% in regular trading, trading at 92.8 HKD/share, with turnover of HKD 244 million. The move was driven by a combination of a major licensing deal and a broad...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144136123","title":"Movement Alert｜Innovent Biologics Falls 3.45% in Regular Trading, Trading at HK$89.85","url":"https://stock-news.laohu8.com/highlight/detail?id=1144136123","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144136123?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:30","pubTimestamp":1784255408,"startTime":"0","endTime":"0","summary":"On July 17, Innovent Biologics fell 3.45% in regular trading, trading at HK$89.85/share, with turnover of HK$499 million.Within the Biotechnology sector where Innovent Biologics belongs, the overall...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652260304","title":"Innovent Biologics (SEHK:1801) Is Up 9.1% After Striking US$1.10 Billion IBI355 Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2652260304","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652260304?lang=en_us&edition=fundamental","pubTime":"2026-07-16 22:28","pubTimestamp":1784212112,"startTime":"0","endTime":"0","summary":"Innovent Biologics recently announced an exclusive license agreement granting Spero Therapeutics rights to develop and commercialize IBI355 outside Greater China, with Innovent eligible for up to approximately US$1.10 billion in upfront and milestone payments plus tiered royalties.\nThe arrangement effectively turns IBI355 into a globally partnered asset, allowing Innovent to keep Greater China rights while leveraging Spero’s international development plans in IgG4-related disease and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-is-up-91-after-striking-us110-bi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-is-up-91-after-striking-us110-bi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01801","LU1969619763.USD","CHAT","BK1161","AGIX","HK0000165453.HKD","VTHR","LU2097828557.USD","LU2097828714.EUR","KURE","LU2242644610.SGD","LU2488822045.USD","LU2097828805.USD","LU2328871848.SGD","LU2097828474.EUR","LU0502904849.HKD","LU0455707207.USD","BK1583","BK1589","AIPO","QTOC","LU2097828631.EUR","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135186577","title":"CLSA Raises Innovent Biologics Price Target to HK$139.9, Citing New Overseas Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=1135186577","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135186577?lang=en_us&edition=fundamental","pubTime":"2026-07-16 14:30","pubTimestamp":1784183417,"startTime":"0","endTime":"0","summary":"CLSA has issued a research report noting that Innovent Biologics (01801) announced on July 14th that it has licensed the rights to its immunology drug IBI355 outside Greater China to Spero...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","KURE","EWH","HK0000165453.HKD","LU2097828474.EUR","LU2328871848.SGD","BK1589","LU0502904849.HKD","LU0455707207.USD","BK1583","LU1969619763.USD","LU2097828631.EUR","BK1161","LU2488822045.USD","LU2242644610.SGD","LU2097828805.USD","LU2097828557.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":-0.0022},{"period":"3month","weight":-0.0088},{"period":"6month","weight":0.1358},{"period":"1year","weight":-0.0856},{"period":"ytd","weight":0.1843}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0974},{"period":"3month","weight":-0.0267},{"period":"6month","weight":-0.0243},{"period":"1year","weight":0.0407},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.116146},{"month":7,"riseRate":0.5,"avgChangeRate":0.019948},{"month":8,"riseRate":0.75,"avgChangeRate":0.005378},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"INNOVENT BIO","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOVENT BIO,01801,INNOVENT BIO股票,INNOVENT BIO股票老虎,INNOVENT BIO股票老虎国际,INNOVENT BIO行情,INNOVENT BIO股票行情,INNOVENT BIO股价,INNOVENT BIO股市,INNOVENT BIO股票价格,INNOVENT BIO股票交易,INNOVENT BIO股票购买,INNOVENT BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}